Skip to main content
Premium Trial:

Request an Annual Quote

BD Segment GeneOhm Settles MRSA IP Tussle with BioMérieux

NEW YORK (GenomeWeb News) - GeneOhm Sciences Canada, a subsidiary of Becton Dickinson, has agreed to settle a dispute with BioMérieux related to “several license agreements” between the companies, BioMérieux said today. The company did not disclose financial details of the settlement.
The dispute began in April, when BioMérieux filed for arbitration proceedings against GeneOhm in the ICC International Court of Arbitration in Paris related to intellectual property rights for diagnostics for methycillin-resistant Staphylococcus aureus.
BioMérieux CEO Stéphane Bancel said the settlement “confirms the relevance” of its IP rights in this particular diagnostics field. Bancel added that the company “intends to play a major role in protecting patients from healthcare-associated infections.”
BioMérieux in April filed another dispute that claimed that BD breached a license agreement related to BD’s Bactec blood culture products. BioMérieux claimed BD was selling those products “in non-licensed fields.”
BD said at the time it saw “no material breach of the agreement, and said it planned to defend its right to sell the Bactec line in those disputed areas.
BioMérieux did not comment today on the status of the Bactec dispute.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more